ATE367158T1 - Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen - Google Patents

Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen

Info

Publication number
ATE367158T1
ATE367158T1 AT98903275T AT98903275T ATE367158T1 AT E367158 T1 ATE367158 T1 AT E367158T1 AT 98903275 T AT98903275 T AT 98903275T AT 98903275 T AT98903275 T AT 98903275T AT E367158 T1 ATE367158 T1 AT E367158T1
Authority
AT
Austria
Prior art keywords
quinazolinenone
neoformations
pharmaceutical compositions
compositions containing
treating malignant
Prior art date
Application number
AT98903275T
Other languages
English (en)
Inventor
Mark Pines
Arnon Nagler
Israel Vlodavsky
Hua-Quan Miao
Original Assignee
Agricultural Res Org
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agricultural Res Org, Hadasit Med Res Service filed Critical Agricultural Res Org
Application granted granted Critical
Publication of ATE367158T1 publication Critical patent/ATE367158T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98903275T 1997-02-11 1998-02-11 Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen ATE367158T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/797,703 US6028075A (en) 1997-02-11 1997-02-11 Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Publications (1)

Publication Number Publication Date
ATE367158T1 true ATE367158T1 (de) 2007-08-15

Family

ID=25171574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98903275T ATE367158T1 (de) 1997-02-11 1998-02-11 Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen

Country Status (11)

Country Link
US (3) US6028075A (de)
EP (1) EP1007044B1 (de)
JP (1) JP2001518075A (de)
KR (1) KR100518106B1 (de)
AT (1) ATE367158T1 (de)
AU (1) AU738516B2 (de)
CA (1) CA2280850C (de)
DE (1) DE69838099T2 (de)
ES (1) ES2290983T3 (de)
IL (1) IL131349A (de)
WO (1) WO1998034613A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
EP0991411A4 (de) * 1997-03-31 2000-05-31 Agricultural Res Org Behandlung von lungenfibrose
ES2255286T3 (es) * 1998-08-13 2006-06-16 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. Inhibicion de los procesos patogenicos relacionados con las lesiones del tejido.
WO2001017531A1 (en) * 1999-09-09 2001-03-15 Hadasit Medical Research Services And Development Company Ltd. Promotion of wound healing
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7893071B2 (en) * 2001-04-23 2011-02-22 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic
EP1425016B1 (de) * 2001-09-05 2010-06-02 Minerva Biotechnologies Corporation Zusammensetzungen und deren verwendung zur behandlung von krebs
CA2459584A1 (en) * 2001-09-05 2003-03-13 Cynthia C. Bamdad Compositions and use thereof in the treatment of cancer
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
US7009049B2 (en) 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
EP1692112A4 (de) 2003-12-08 2008-09-24 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7816347B2 (en) * 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
JP2008531547A (ja) * 2005-02-23 2008-08-14 コルガード バイオファーマシューティカルズ リミテッド キナゾリノン誘導体であるハロフジノンの単離されたｄ−エナンチオマーの医薬組成物
AU2006267841B2 (en) * 2005-07-07 2011-12-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19, and methods of using same
US20070160640A1 (en) * 2006-01-12 2007-07-12 Eun-Hyun Jang Halofuginone delivering vascular medical devices
WO2007120606A2 (en) * 2006-04-10 2007-10-25 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
US8668703B2 (en) * 2006-12-01 2014-03-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
EP2111449B1 (de) 2007-01-16 2012-03-07 Yissum Research Development Company of the Hebrew University of Jerusalem Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
US8410120B2 (en) 2007-01-21 2013-04-02 Mark Pines Composition and method for treating or preventing skeletal muscle fibrosis
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
CA2737219C (en) 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
CA2861840C (en) 2012-01-13 2020-12-15 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
WO2015034330A1 (ko) * 2013-09-09 2015-03-12 가톨릭대학교 산학협력단 헬로퓨지농을 유효성분으로 포함하는 골질환 치료 또는 예방용 조성물
CN105497091B (zh) * 2016-01-05 2020-01-24 香港浸会大学 一种用于抗癌的常山酮青蒿倍半萜内酯类化合物的组合物及其应用
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
DE2934069A1 (de) * 1979-08-23 1981-03-12 Hoechst Ag, 6000 Frankfurt Mittel gegen theileriosen und seine verwendung.
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Also Published As

Publication number Publication date
EP1007044A4 (de) 2001-03-07
DE69838099T2 (de) 2008-04-30
USRE39574E1 (en) 2007-04-17
EP1007044B1 (de) 2007-07-18
US6028075A (en) 2000-02-22
IL131349A (en) 2004-08-31
US6420371B1 (en) 2002-07-16
IL131349A0 (en) 2001-03-19
WO1998034613A1 (en) 1998-08-13
AU6004998A (en) 1998-08-26
KR100518106B1 (ko) 2005-10-04
JP2001518075A (ja) 2001-10-09
ES2290983T3 (es) 2008-02-16
AU738516B2 (en) 2001-09-20
CA2280850C (en) 2004-01-13
EP1007044A1 (de) 2000-06-14
CA2280850A1 (en) 1998-08-13
KR20000070996A (ko) 2000-11-25
DE69838099D1 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
DE69838099D1 (de) Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
DE69807115D1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
MX9604145A (es) Metodos y composiciones utiles para la inhibicion de angiogenesis.
ATE253892T1 (de) Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
DE69828042D1 (de) Verfahren und zusammensetzung zur behandlung von krebs
BR9913564A (pt) Tratamento de angiopatias microvasculares
TR199901104T2 (xx) Farmas�tik bile�ikler.
DE69637178D1 (de) N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
DE60334711D1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
GB9907571D0 (en) Compounds
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
BG103632A (en) Pharmaceutical compositions containing ibuprophene and domperidon for migraine treatment
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
DK0850062T3 (da) Anvendelse af halofuginon til fremstilling af et medikament til svækkelse af neovaskularisering og til behandling af maligne tumorer hos mennesker
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
SE9803623D0 (sv) New therapeutic application
MX9703610A (es) Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties